

Pharmaceutical Preformulation and Formulation

A Practical Guide from Candidate Drug
Selection to Commercial Dosage Form

Edited by Mark Gibson

MYLAN EXHIBIT 1022

PHARMACEUTICAL PREFORMULATION AND FORMULATION

**A Practical Guide from
Candidate Drug Selection to
Commercial Dosage Form**

Mark Gibson

Editor



IHS[®] Health Group

An IHS[®] GROUP Company

Your Enterprise Solution to □
Global Healthcare Knowledge



Library of Congress Cataloging-in-Publication Data

Catalog record is available from the Library of Congress

This book contains information obtained from authentic and highly regarded sources. Reprinted material is quoted with permission, and sources are indicated. A wide variety of references are listed. Reasonable efforts have been made to publish reliable data and information, but the authors and the publisher cannot assume responsibility for the validity of all materials or for the consequences of their use.

Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage or retrieval system, without prior permission in writing from the publisher.

The consent of CRC Press LLC does not extend to copying for general distribution, for promotion, for creating new works, or for resale. Specific permission must be obtained in writing from CRC Press LLC for such copying.

Direct all inquiries to CRC Press LLC, 2000 N.W. Corporate Blvd., Boca Raton, Florida 33431.

Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation, without intent to infringe.

Visit the CRC Press Web site at www.crcpress.com

© 2004 by Interpharm/ CRC

No claim to original U.S. Government works
Library of Congress Card Number 1-57491-120-1
Printed in the United States of America 1 2 3 4 5 6 7 8 9 0
Printed on acid-free paper

4

Biopharmaceutical Support in Candidate Drug Selection


Anna-Lena Ungell
Bertil Abrahamsson

AstraZeneca
Mölndal, Sweden

Administration via the oral route has been, and still is, the most popular and convenient route for patient therapeutics. However, even though it is the most convenient route, it is not the simplest route, as the barriers of the gastro-intestinal (GI) tract are in many cases difficult to circumvent. The main barriers of the GI tract to systemic delivery are the environment in the stomach and intestinal lumen, the presence of different enzymes, the physical barrier of the epithelium and the liver extraction. These barriers are of functional importance for the organism in controlling intake of water, electrolytes and food constituents and still remain a complete barrier to harmful organisms such as bacteria, viruses and toxic compounds.

Generally, drug absorption from the GI tract requires that the drug is brought into solution in the GI fluids and that it is capable of crossing the intestinal membrane into the systemic circulation. It has therefore been suggested that the drug must be in its molecular form before it can be absorbed. Therefore, the rate of dissolution of the drug in the GI lumen can be a rate-limiting step in the absorption of drugs given orally. Particles of drugs, e.g., insoluble crystalline forms or specific delivery systems such as liposomes, are generally found to be absorbed to a very small extent. The cascade of events from release of the drug from its dosage form, i.e. *dissolution* of the drug in the gut lumen, *interactions* and/or degradation within the lumen and the *uptake* of its molecular form across the intestinal membrane into the systemic circulation, is schematically shown in Figure 4.1. For rapid and effective design and development of new drug products, methods for drug absorption are required that describe the different steps involved before and during the absorption process. The need for such specific

Figure 4.1 Drawing showing the different steps in the absorption process including the dissolution of the compound from the solid dosage form, interactions with the dissolved material in the gastro-intestinal lumen and the uptake of the compound through the epithelial membrane.



methods is determined by the information on the rate-limiting step in the cascade of events (e.g., solubility, permeability or metabolic instability limited). The results from these methods act as a guide to a more efficient discovery process in which resources are given to optimising structures that lead to the selection of a good drug candidate with well-defined pharmacokinetic and physicochemical properties. A method now available is multivariate analysis for analysing large data sets. Screening and optimisation of several parameters in parallel, e.g., permeability, metabolic stability, solubility, potency, duration and toxicity, represent a growing area for rationalising drug discovery using multivariate statistical models (Eriksson et al. 1999). The importance of this is obvious: There is no point in using resources to increase the potency of an oral drug candidate if the drug is not predicted to be orally bioavailable. The consideration of biopharmaceutical properties in the selection of candidate drugs has also been shown in a recent survey, based on statistics published by the Pharmaceutical and Research Manufacturers of America (PhRMA), to be the most common reason for terminating drug development projects in the clinical phase.

The dissolution rate and/or the aqueous solubility of the drug will also affect the outcome of studies using biological methods, in very early phases of screening. If not dissolved in the test system, low solubility drugs will not appear on the receiver side/blood side of a membrane or will show incomplete absorption *in vivo*. Consequently, the drug will be considered a low permeability drug and be discarded as being of no potential use as a systemically active drug. The situation is even more complex, since there are also mechanistic membrane processes that can give the same result. Such processes include drug efflux systems that transport the drug from inside the epithelial cell to the lumen of the intestine [e.g., efflux proteins (Hunter and Hirst 1997)] or metabolism during transport and adhesion to plastics in the test system (Table 4.1). The evaluation of the reason for low transport is therefore crucial for the design of proper screening procedures.

In the drug discovery process, the selection of a suitable candidate drug is the milestone for continuing into a costly development and clinical phase. Some *optimal absorption criteria* from a biopharmaceutical point of view are shown below:

- High permeability coefficient (determined using *in vitro* assays such as Caco-2 cell monolayers, Ussing chambers, intestinal perfusions, etc.; see below) throughout the GI tract [Extended Release (ER) formulation]

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.